Dr Manish SaxenaClinical Co-Director, William Harvey Clinical Research Centre and Deputy Director Research, Barts Health NHS Trust and QMULCentre: Clinical Pharmacology and Precision Medicine, Clinical Research Centre Email: m.saxena@qmul.ac.ukTelephone: +44(0) 20 7882 3856Twitter: @DrManishNSaxena ProfileResearchKey PublicationsSponsorsCollaboratorsNewsProfileDr Saxena completed MBBS in 1996 and has been practising medicine for over 25 years. He completed a Master’s degree in Health Care Research and Clinical Drug Development with distinction from Queen Mary University of London. He is Deputy Director for Research for Barts Health NHS Trust/QMUL and Clinical Co-Director at the William Harvey Clinical Research Centre. He works at Barts Hypertension Clinic as a European Accredited specialist in hypertension. Dr Saxena has worked with the Health Research Authority as an expert member for over 12 years and has been chair of the National Research ethics committee for over 7 years. He is part of the National Institute for Health and Care Research (NIHR) leadership group as Speciality Research Lead for Diabetes for North Thames CRN. He is Academic Lead for Innovation and Commercial Partnerships for Barts Faculty of Medicine.Research Group members Armida Balawon, Ania Michalska, Francis Galera, Benildo Quiros, Aaron Jairo Oblena, Arooj Ayub, Brenda Roberts, Rizwana Ayub Summary Dr Saxena is a cardiovascular (CV) physician passionate about developing novel therapies for CV prevention and treatment. As UK Chief Investigator and Barts lead, he leads on several studies in high-risk patients with dyslipidaemia (with second generation PCSK9i such as Inclisiran and oral PCSK9i, Bempedoic Acid, CETP modulators); in T2DM and CHF (SGLT2i, GLP-1, Aldose reductase inhibitors). He runs studies in Hypertension pioneering pharmacotherapy (SiRNA) and novel device therapies such as Renal Denervation, Carotid sinus modulation and Arterio-venous coupler besides collaborating on novel BP monitoring technologies such as Life light using remote PPG technology. He also works with patients with autonomic dysfunction and has run studies in patients with neurogenic orthostatic hypotension. His work also includes studies in other CV therapeutics involving anti-platelets, new oral anti-coagulants, dementia prevention and treatment. Memberships and awards Member European Society of HTN Member European Society of Cardiology Member Joint British and Irish Hypertension Society Publications Zappe D, Saxena M, Desai A et al. (2024). Abstract 4138847: Home Blood Pressure Reductions With Zilebesiran In Patients With Mild-To-Moderate Hypertension Are Consistent With Ambulatory And Office Blood Pressure Reductions In The KARDIA-1 Study. nameOfConference DOI: 10.1161/circ.150.suppl_1.4138847 QMRO: qmroHref Collier D, Taylor M, Godec T et al. (2024). Do more with less? Impact of personalized very low doses of amlodipine in the PERSONAL-CovidBP trial. nameOfConference DOI: 10.1093/eurheartj/ehae666.2595 QMRO: qmroHref Saxena M, Aswad A, Badariene J et al. (2024). Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive. nameOfConference DOI: 10.1093/eurheartj/ehae666.2593 QMRO: qmroHref Bloch MJ, Kirtane AJ, Azizi M et al. (2024). 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. nameOfConference DOI: 10.1038/s41440-024-01854-w QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100327 Greene SJ, Böhm M, Bozkurt B et al. (2024). Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry. nameOfConference DOI: 10.1016/j.cardfail.2024.08.048 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100390 Unverdorben M, Colonna P, Jin J et al. (2024). Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program. nameOfConference DOI: 10.1177/10760296241260728 QMRO: qmroHref Saxena M (2024). Vaccines against angiotensin receptors as a potential treatment for hypertension. nameOfConference DOI: 10.1097/hjh.0000000000003729 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100795 Colonna P, Souza J, Saxena M et al. (2024). Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme. nameOfConference DOI: 10.1093/europace/euae102.236 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100654 Saxena M, Aswad A, Badariene J et al. (2024). ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY. nameOfConference DOI: 10.1097/01.hjh.0001020464.05231.4a QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100797 Hall CV, Twelves JL, Saxena M et al. (2024). Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial. nameOfConference DOI: 10.1017/s0007114524000904 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100626 View Profile Publication Page Sponsors Novartis Alnylam Astra Zeneca MSD Boehringer Ingelheim New Amsterdam Pharma Applied Therapeutics Amgen Moderna Esperion Inc Recor Medical Inc Ablative Solutions Inc Medtronics Vascular Dynamics Inc Xim BP Novonordisk Collaborators Prof Anoop Chauhan, MBE, Director Research & Innovation, Portsmouth Hospitals NHS Trust Prof Melvin Lobo, Director Barts BP Services Prof Feng He, Prof of Global Health Research, Wolfson Institute Dr David Collier, Deputy Director, Barts CTU Antonio Sotiris, Chief Pharmacist Barts Hospital Oxford Clinical Trials Unit Blood Pressure UK NewsJune 2022 A new jab for patients with high blood pressure could replace daily tablets - Mirror Minimally-invasive procedure could offer hope to patients with high blood pressure - News Medical & Life Sciences New procedure found to reduce blood pressure in hypertension patients - Health Europa May 2022 Barts Health Trust held an event for International Clinical Trials Day 2022 - Trials Connect April 2022 6-month-to-month blood pressure injection could before long substitute a day-to-day pill - Euro News Source Free from tablets? UK begins trial for biannual injection to treat high blood pressure - Khaleej News Six-monthly blood strain injection may quickly substitute a every day tablet - Polish News Why I won't have another lousy night's sleep -Malcolm's story - Blood Pressure UK Twice-yearly jabs for high blood pressure could replace need to take daily pills - The Telegraph Barts Health and Queen Mary scientists to trial world-first long-acting injection for high blood pressure - Barts Health NHS Trust Twice-a-year jab to replace daily blood pills - Express Twice-yearly jab to lower blood pressure could be offered as an alternative to daily pills by 2025 - Mail Online World-first jab could treat one of biggest silent killers – replacing daily drugs - The Sun NHS Trust to trial world’s first high blood pressure injection - National Health Executive Medical breakthrough could mean big changes for people with high blood pressure - Planet Radio Improving access to innovative treatments: A patient centred approach - UCL Partners Biannual injection could keep blood pressure in check without daily pill - China Daily December 2021 Lifelight raises $8m to turn devices in self-monitoring platforms - MedTech News June 2021 Procedure using ultrasound energy found to treat high blood pressure - Eureka alerts November 2010 Barts trials treatment for high blood pressure with revolutionary potential - Queen Mary University of London Back to top